European Association of Urology 41st Annual Congress (EAU26)

London, UK 13 March 2026 - 16 March 2026

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026 by

A secondary bladder cancer (SBC) rarely occurs among patients with localized prostate cancer who have been treated with radiotherapy (RT), but the incidence rate is not insignificant, reports a study presented at EAU 2026. When it does appear, it usually becomes the primary cause of death in this population.

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 by

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026 by

The minimally invasive MRI-guided transurethral ultrasound ablation (TULSA) for prostate cancer is associated with better safety and periprocedural outcomes compared with robotic prostatectomy, according to the early results of the phase III CAPTAIN trial.

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

29 Mar 2026 by

Recurrent urinary tract infection (UTI) care in primary and secondary care settings appears to be characterized by low guideline adherence, with a substantial number of women still being treated with antibiotics and subjected to low-yield investigations, according to a study.

Antibiotics, low-yield investigations for recurrent UTI prevail in real-world practice

29 Mar 2026

Mirabegron a potentially safer alternative to solifenacin for paediatric OAB

28 Mar 2026 by

In the treatment of overactive bladder (OAB) in children, mirabegron demonstrates efficacy similar to that of solifenacin but has a better safety profile, according to a meta-analysis presented at the annual EAU Congress.

Mirabegron a potentially safer alternative to solifenacin for paediatric OAB

28 Mar 2026

Vaginal laser therapy may prevent recurrent cystitis in postmenopausal women

28 Mar 2026 by

The use of vaginal laser therapy (VLT) significantly reduces cystitis episodes and improves vaginal health in postmenopausal women, according to a study presented at EAU26.

Vaginal laser therapy may prevent recurrent cystitis in postmenopausal women

28 Mar 2026

2-year data support nerve-sparing technique in prostate cancer surgery

27 Mar 2026 by

An updated 24-month analysis of the NeuroSAFE PROOF study continues to support robot-assisted radical prostatectomy (RARP) guided by the nerve-sparing NeuroSAFE technique in men with prostate cancer.

2-year data support nerve-sparing technique in prostate cancer surgery

27 Mar 2026

Bladder problems burden people with multiple sclerosis

26 Mar 2026 by

Bladder dysfunction is among the top 10 most frequently reported functional domains affecting people living with multiple sclerosis (MS), reports a study presented at EAU 2026.

Bladder problems burden people with multiple sclerosis

26 Mar 2026

Open vs robot-assisted kidney transplant: Which approach is safer for ESKD patients?

26 Mar 2026 by

Robot-assisted kidney transplantation falls short of establishing its superiority over an open surgery approach, but it does yield reductions in complication rates among adults with end-stage kidney disease (ESKD), according to the ORAKTx study presented at EAU 2026.

Open vs robot-assisted kidney transplant: Which approach is safer for ESKD patients?

26 Mar 2026

Pre-TURBT mitomycin-C improves RFS in NMIBC

26 Mar 2026 by

In the updated 5-year analysis of a randomized phase II trial, administering two doses of intravesical mitomycin-C (MMC) immediately before transurethral resection of bladder tumour (TURBT) improves recurrence-free survival (RFS) in individuals with non-muscle invasive bladder cancer (NMIBC).

Pre-TURBT mitomycin-C improves RFS in NMIBC

26 Mar 2026